Prosecution Insights
Last updated: November 04, 2026
Application No. 18/495,744

PRODUCT FOR DIAGNOSING CONGENITAL SCOLIOSIS AND APPLICATION THEREOF

Non-Final OA §102§103§112
Filed
Oct 26, 2023
Priority
Jun 24, 2014 — CN 201410284657.5 +4 more
Examiner
GOLDBERG, JEANINE ANNE
Art Unit
1682
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Peking Union Medical College Hospital Peking Union Medical College And Chinese
OA Round
1 (Non-Final)
46%
Grant Probability
Moderate
1-2
OA Rounds
5m
Est. Remaining
86%
With Interview

Examiner Intelligence

Grants 46% of resolved cases
46%
Career Allowance Rate
380 granted / 836 resolved
-14.5% vs TC avg
Strong +41% interview lift
Without
With
+40.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
72 currently pending
Career history
924
Total Applications
across all art units

Statute-Specific Performance

§101
23.0%
-17.0% vs TC avg
§103
19.6%
-20.4% vs TC avg
§102
17.4%
-22.6% vs TC avg
§112
29.8%
-10.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 836 resolved cases

Office Action

§102 §103 §112
DETAILED CORRESPONDENCE Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This action is in response to the papers filed August 13, 2026. Currently, claims 1-15, 17-20 are pending. Claims 8-10, 14, 18-20 have been withdrawn as drawn to non-elected subject matter. Election/Restrictions Applicant's election without traverse of Group II, and a combination of TBX6 gene deletion and hypomorphic haplotype mutations of two SNP sites and microdeletion 0.6Mb in the paper filed August 13, 2026 is acknowledged. The requirement is still deemed proper and is therefore made FINAL. Priority This application claims priority to PNG media_image1.png 65 455 media_image1.png Greyscale The application also claims priority to two foreign applications CN 201410284657 and 201410572962, filed June 24, 2014 and October 24, 2014 respectively. It is noted that a translation of the foreign document has not been received. The instant application is a CIP. The newly added limitations of performing surgical intervention is not part of the original applications. Thus, the instant claims are entitled to the benefit of October 26, 2023. Drawings The drawings are acceptable. Claim Rejections - 35 USC § 112- Second Paragraph The following is a quotation of 35 U.S.C. 112(b): (B) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claims 1-7, 11-13, 15, 17 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. A) The claims are directed to a method of treating a subject with congenital scoliosis by determining whether the subject has a mutation and performing surgical intervention on the patient. “The patient” in the final step of the method appears to refer back to only subjects who have a TBX6 associated congenital scoliosis (TACS). However, the preamble is directed to treating a subject. Thus it is unclear if the patient and the subject are the same. Merely changing “the patient” to “the subject” will not clarify because then it will be confusing whether all subjects are treated or only TACS subjects. Clarification is required. B) Claim 13 is indefinite because it is unclear whether the claim requires performing QPCR with all six of the recited primers. It is unclear whether the primers consist of SEQ ID NO: 1-6 or the primers may be longer than the recited primers, i.e. comprising SEQ ID NO: 1-6. The language “the sequences of the primers are as follows:” is not clear. Clarification is required. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Claim(s) 1-7, 11-12, 15, 17 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Zhang et al. (Frontiers in Medicine, Vol. 9, No. 941468, August 11, 2022). Zhang teaches a method for determining whether a subject has a mutation in TBX6 gene by genotyping and molecularly diagnosing TACS (abstract). Zhang teaches the clinical characteristics and surgical treatment options were collected and surgery was performed and postoperative prognoses was followed (abstract). Zhang teaches eight patients were molecularly diagnosed with TACS and the patients receive posterior hemivertebra resection combined with segmental fusion, a surgical intervention (abstract)(limitations of Claim 17). Zhang teaches performing exon sequencing from peripheral blood samples (page 2, col. 2)(limitations of Claims 11-12). Zhang teaches rs3809624 and rs3809627 were haplotyped and sequenced (page 3, col. 2). PNG media_image2.png 201 729 media_image2.png Greyscale Zhang also teaches detecting 16p11.2 deletions in 4 patients as well as nonsense mutations and frameshifts (limitations of Claim 5). PNG media_image3.png 107 553 media_image3.png Greyscale Zhang teaches that TBX6 deletions are microdeletions of about 0.6 Mb in length (limitations of Claim 6). Patients 2-5 have 16p11.2 deletions and C-A haplotypes (limitations of Claim 7)(Table 1). Claim(s) 1-7, 11-12, 15, 17 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Liu et al. (Am. College of Medical Genetics and Genomics, Vol. 21, No. 7, pages 1548-1558, July 2019). Liu teaches TBX6-associated congenital scoliosis (TACS) as a subtype of congenital scoliosis. Liu teaches determining the genotype in patients for TBX6 genotypes. Liu teaches developing a TACScore (abstract) to assist in clinical recognition of TBX6-associated CS. Liu teaches performing genetic analysis on subjects to detect 16p11.2 deletions as well as TBX6 gene and its upstream regions (page 1549, col. 2). Liu teaches patients with deletion CNV results in deletion of 0.6Mb 16p11.2 deletion CNV (page 1556, col. 2). In a particular case Liu teaches patient XH101 was diagnosed as having CS with an L2 hemivertebra at 3 years of age, and molecular testing indicated that she had a frameshift variant in TBX6 with the in trans T-C-A risk haplotype. The TACS diagnosis was made by integrating the molecular testing and clinical phenotypes (page 1556, col. 2). Liu teaches performing L2 hemivertebra resection with short segment internal fixation and removed the instrument at 3 years post operation when she had a balanced spine (page 1556, col. 2). Thus Liu teaches each limitation of the instant claims. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim 13 is/are rejected under 35 U.S.C. 103 as being unpatentable over Zhang et al. (Frontiers in Medicine, Vol. 9, No. 941468, August 11, 2022) in view of Wu et al. (US 2017/0226584, August 2017). Zhang teaches a method for determining whether a subject has a mutation in TBX6 gene by genotyping and molecularly diagnosing TACS (abstract). Zhang teaches the clinical characteristics and surgical treatment options were collected and surgery was performed and postoperative prognoses was followed (abstract). Zhang teaches eight patients were molecularly diagnosed with TACS and the patients receive posterior hemivertebra resection combined with segmental fusion, a surgical intervention (abstract)(limitations of Claim 17). Zhang teaches performing exon sequencing from peripheral blood samples (page 2, col. 2)(limitations of Claims 11-12). Zhang teaches rs3809624 and rs3809627 were haplotyped and sequenced (page 3, col. 2). PNG media_image2.png 201 729 media_image2.png Greyscale Zhang also teaches detecting 16p11.2 deletions in 4 patients as well as nonsense mutations and frameshifts (limitations of Claim 5). PNG media_image3.png 107 553 media_image3.png Greyscale Zhang teaches that TBX6 deletions are microdeletions of about 0.6 Mb in length (limitations of Claim 6). Patients 2-5 have 16p11.2 deletions and C-A haplotypes (limitations of Claim 7)(Table 1). Zhang does not teach primers for amplifying the 16p11.2 deletion in TBX6. However, Wu teaches primers for amplifying microdeletions in 16p11.2 for diagnosis. Wu teaches SEQ ID NO: 1-6 of the instant application. Therefore, it would have been prima facie obvious prior to the effective filing date of the claimed invention to have used known primers of SEQ ID NO: 1-6 for amplifying the TBX6 microdeletions of 0.6Mb taught by Zhang. The ordinary artisan would have been motivated to have used known primers taught in the art. Conclusion No claims allowable over the art. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Khalchitsky et al. (Pediatric Traumatology, Orthopaedics and Reconstructive Surgery, Vol. 9, No. 3, 2021) teaches a review of the TBX6 gene on the development of congenital spinal deformities in children. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JEANINE ANNE GOLDBERG whose telephone number is (571)272-0743. The examiner can normally be reached Monday-Friday 6am-3:30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Wu-Cheng Winston Shen can be reached on (571)272-3157. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JEANINE A GOLDBERG/Primary Examiner, Art Unit 1682 October 27, 2026
Read full office action

Prosecution Timeline

Oct 26, 2023
Application Filed
Oct 29, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12760375
DETECTION OF TUMOR-DERIVED DNA IN CEREBROSPINAL FLUID
2y 4m to grant Granted Oct 13, 2026
Patent 12753443
METHODS RELATING TO ANTI-IL-1 THERAPY AND ANTI-IL-6 THERAPY AND HYPERSENSITIVITY
3y 2m to grant Granted Oct 06, 2026
Patent 12738355
METHODS OF TREATING BREAST CANCER
3y 5m to grant Granted Sep 15, 2026
Patent 12729404
METHOD AND KIT FOR TESTING DRUG HYPERSENSITIVITY REACTIONS CAUSED BY SULFONAMIDE DERIVATIVE-BASED ANTIEPILEPTIC DRUG AND USE OF THE KIT
3y 6m to grant Granted Sep 08, 2026
Patent 12698539
COMPOSITIONS AND METHODS FOR THE DETECTION OF A CHROMOSOMAL TRANSLOCATION IN BRASSICA NAPUS
4y 4m to grant Granted Aug 04, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
46%
Grant Probability
86%
With Interview (+40.7%)
3y 6m (~5m remaining)
Median Time to Grant
Low
PTA Risk
Based on 836 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month